Compare
Structure Therapeutics Inc. vs Acadia Pharmaceuticals Inc vs Ligand Pharmaceuticals Inc vs Amphastar Pharmaceuticals, Inc.
| Latest fiscal year | Structure Therapeutics Inc. GPCR | Acadia Pharmaceuticals Inc ACAD | Ligand Pharmaceuticals Inc LGND | Amphastar Pharmaceuticals, Inc. AMPH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.07B | $268.09M | $719.89M |
| Revenue growth (YoY) | n/a | +11.9% | +60.4% | -1.7% |
| Gross margin | n/a | 91.7% (computed) | n/a | 49.5% |
| Operating margin | n/a | 9.8% | 15.3% | 19.5% |
| Net margin | n/a | 36.5% | 46.4% | 13.6% |
| Net income | -$141.20M | $391.00M | $124.45M | $98.09M |
| EPS (Diluted) | -$0.80 | $2.30 | $6.13 | $2.03 |
| Operating cash flow | -$222.20M | $109.84M | $49.36M | $156.12M |
| Free cash flow | -$225.81M | $105.15M | $48.91M | $121.23M |
| Cash & equivalents | $799.62M | $177.69M | $174.93M | $170.18M |
| Total assets | $1.58B | $1.56B | $1.56B | $1.63B |
| Total liabilities | $67.54M | $336.81M | $543.42M | $840.49M |
| Shareholders' equity | $1.52B | $1.23B | $1.02B | $788.80M |
| Return on year-end equity | -9.3% | 31.9% | 12.2% | 12.4% |
| Shares outstanding | 212.51M | 170.31M | 19.77M | 45.65M |
Revenue, most recent five fiscal years
| Fiscal year | Structure Therapeutics Inc. | Acadia Pharmaceuticals Inc | Ligand Pharmaceuticals Inc | Amphastar Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $1.07B Ended 2025-12-31 | $268.09M Ended 2025-12-31 | $719.89M Ended 2025-12-31 |
| 1 year earlier | n/a | $957.80M Ended 2024-12-31 | $167.13M Ended 2024-12-31 | $731.97M Ended 2024-12-31 |
| 2 years earlier | n/a | $726.44M Ended 2023-12-31 | $131.31M Ended 2023-12-31 | $644.39M Ended 2023-12-31 |
| 3 years earlier | n/a | $517.24M Ended 2022-12-31 | $196.25M Ended 2022-12-31 | $498.99M Ended 2022-12-31 |
| 4 years earlier | n/a | $484.14M Ended 2021-12-31 | $241.54M Ended 2021-12-31 | $437.77M Ended 2021-12-31 |